

HETEROCYCLES, Vol. 89, No. 4, 2014, pp. 1055 - 1064. © 2014 The Japan Institute of Heterocyclic Chemistry
Received, 23rd January, 2014, Accepted, 7th February, 2014, Published online, 14th February, 2014
DOI: 10.3987/COM-14-12948

SYNTHESIS AND ANTIMALARIAL ACTIVITY OF SOME NEOCRYPTOLEPINE ANALOGUES CARRYING A MULTIFUNCTIONAL LINEAR AND BRANCHED CARBON-SIDE CHAINS

Elkhabiry Shaban,¹ Kathryn J. Wicht,² Ning Wang,¹ Zhen-Wu Mei,¹ Ikuya Hayashi,¹ Ahmed Abdel Aleem El Gokha,⁴ Marcel Kaiser,³ Ibrahim El Tantawy El Sayed,^{1,4} Timothy J. Egan,^{2*} and Tsutomu Inokuchi^{1*}

¹Division of Chemistry and Biotechnology, Graduate School of Natural Science and Technology, Okayama University, Okayama, Japan, ²Department of Chemistry, University of Cape Town, South Africa, ³Swiss Tropical and Public Health Institute, Basel, Switzerland, ⁴Chemistry Departments, Faculty of Science, El Menoufeia University, Shebin El Koom, Egypt

E-mail*: Timothy.Egan@uct.ac.za, inokuchi@cc.okayama-ac.jp

Abstract – The synthesis and *in vitro* antimalarial activity of several neocryptolepine analogues carrying either a linear or branched dibasic side chain at C11 are described. Many of these neocryptolepine analogues have low nanomolar antimalarial activity against the chloroquine-sensitive *P. falciparum* strain (NF54). The data also demonstrated that a branched structural motif is not superior for antimalarial activity over a linear side chain, but their thioureido derivatives showed lower cytotoxicity than the linear one. Ureido and thioureido derivatives also showed stronger β -haematin inhibition than the corresponding free amines.

The emergence and spread of chloroquine-resistant *Plasmodium falciparum* parasites has been a major global health problem and contributes significantly to the continued high prevalence of malaria.^{1,2} New, safe, and effective drugs active against multidrug resistant *P. falciparum* strains are thus urgently needed.^{1,3} Medicinal plants have long been used for treating parasitic diseases, including malaria, and constitute an important source of new molecules for lead optimization programs, as exemplified by the success of artemisinin and its derivatives.⁴⁻⁹ Neocryptolepine, **1** (Figure 1), is an indolo[2,3-*b*]quinoline alkaloid isolated as a minor alkaloid alongside its major regio-isomer cryptolepine **2** from the roots of

Cryptolepis sanguinolenta, a shrub used in traditional medicine for the treatment of malaria in Central and West Africa.^{10,11}





Figure 1. Indoloquinolines from *Cryptolepis sanguinolenta*

In addition, neocryptolepine **1** also exerts a broad range of potential biological applications^{12–21} and appeared to have lower cytotoxicity compared to cryptolepine **2**.^{22,23} However, several neocryptolepine analogues have been described to possess DNA intercalating activity and are reported as anticancer drugs.^{15,21} Based on our recent findings, it was speculated that substitution of neocryptolepine could be favorable for more potent and selective antimalarial activities and several series of substituted neocryptolepines have been synthesized.^{12–20} These promising results prompted us to investigate structure-activity relationships (SAR) with respect to the structural requirements of side-chains at C-11 of the neocryptolepine scaffold for improved antiplasmodial activity and selectivity relative to the lead compound, neocryptolepine **1**. In this paper, we have explored a set of neocryptolepine analogues having diversified side-chains by varying the structure and length of the linker between the two nitrogen atoms as well as the substitution pattern and basicity of the distal amino group.

The synthetic strategy for neocryptolepine analogues **8a–g** was based on nucleophilic aromatic substitution (S_NAr) reactions of the key intermediate 11-chloro-substituted neocryptolepines **7** obtained *via* Scheme 1. This method was used for synthesis of neocryptolepines with substitutions on the B ring (C-11 position). Thus, a series of neocryptolepines with different side chains at C-11 were prepared starting from methyl 1*H*-indole-3-carboxylate (**3**) and *N*-methylaniline derivatives **4**. The intermediate methyl 2-(phenylamino)-1*H*-indole-3-carboxylates **5** were obtained *via* chlorination with *N*-chlorosuccinimide in the presence of 1,4-dimethylpiperazine followed by addition of the aniline derivative as a trichloroacetate salt. Cyclization of **5** was achieved by heating in boiling diphenyl ether to afford 5,6-dihydro-11*H*-indolo[2,3-*b*]quinolin-11-ones **6**, which were chlorinated with $POCl_3$ to give 11-chloroneocryptolepines **7**, the key intermediates for diversification. Subsequent amination of **7** with various 1,2-diaminoethanes and 1,3-diaminopropanes by heating yielded the target compounds **8a–g** as depicted in Scheme 1.










Scheme 1. Synthesis of indolo[2,3-*b*]quinolones with substituents at C2 and C11. Reagents and conditions: (i) (a) *N*-chlorosuccinimide, 1,4-dimethylpiperazine, CH₂Cl₂, 0 °C, 2 h; (b) trichloroacetic acid, rt, 2 h; (ii) diphenyl ether, reflux, 1–3 h; (iii) POCl₃, toluene, reflux, 6–12 h; (iv) appropriate amines, 120 °C, 4 h.

The synthesized compounds **8a–g** were evaluated for their *in vitro* antimalarial activity against the chloroquine-sensitive *P. falciparum* strain (NF54). The corresponding IC₅₀ values together with their cytotoxicity determined using mammalian L6 cells are presented in Table 1. In this study, we have chosen the side chain portion using a propyl spacer (three carbons) for the aminoalkylamino substituent at the C11, because incorporation of such shorter side chain variant proved to be of important element for antimalarial activity.^{24,25} The side chains at C11 of **8** were introduced by the reaction of **7** with branched 1,2-diaminoethane or 1,3-diaminopropanes, and their *in vitro* antimalarial activity was compared with that of **7** with no branched aminoalkylamino-substituent at C-11. IC₅₀ values for compounds **8a–g** range from 11.8 to 232.5 nM, which represent a significant improvement in antiplasmodial activity over the neocryptolepine **1** (1580 nM), but not as good as the well-known antimalarial drugs, artemisinin (4.3 nM) and chloroquine (9.4 nM). Inspection of the data in Table 1 allows the following conclusions to be drawn. Firstly, compounds containing a linear 3-aminopropylamino group with a three carbon spacer, e.g., **8a**, **8c**, generally present better antiplasmodial activity than those with the corresponding branched chains, e.g., **8b**, **8d**. The type of pendant group residing on the spacer also has influence on antiplasmodial activity, for example, replacing the geminal dimethyl group in **8d** with hydroxy group as in **8e** substantially improved the antiplasmodial activity. Also the number of pendant methyl groups on the spacer has an influence as it appears when the results of side-chain with two carbon atom spacer and branched with one methyl group, e.g., **8f**, and two geminal dimethyl groups, e.g., **8g**, are compared. The results showed that such variation has a slight effect on activity but a remarkable effect on cytotoxicity and subsequently improved selectivity index (SI) against the parasite. For example, **8g** has a SI of over 100 compared with **8e**, which has a SI below 20. It should also be noted that the antiplasmodial activity as well as the selectivity indices increased

by adding a chloro substituent at C-2 on the A-ring in combination with a 11-aminoalkylamino side-chain on the neocryptolepine core, as in compounds **8c** and **8d**, when compared with the corresponding nonchlorinated analogues **8a** and **8b**.

Table 1. The antiplasmodial activity against *P. falciparum* (CQS: NF54) and cytotoxicity towards mammalian L6 cells of the neocryptolepine derivatives **8a–g**.


Compound	R ¹	R ²	Yield %	L6 cells IC ₅₀ nM ^b	NF 54 IC ₅₀ nM ^b	SI ^a L6/NF54	β-Heamatin inhibition IC ₅₀ μM ^b
Neocryptolepine 1	H	H	-	3194	1580	2.0	
7	H	Cl	-	1459	2055	0.7	-
8a	H		96	279.2	78.8	3.5	-
8b	H		84	1475.0	232.5	6.3	293.90
8c	Cl		92	268.6	11.8	22.8	-
8d	Cl		95	2175.5	108.2	20.1	748.50
8e	Cl		82	1352.8	69.9	19.4	73.02
8f	Cl		87	675.9	27.4	24.7	156.90
8g	Cl		90	2644.1	26.1	101.3	138.10
Podophyllotoxin	-	-	-	14.5	-	-	
Chloroquine	-	-	-	-	9.4	-	34.75
Artemisinin	-	-	-	-	4.3	-	

^aSelectivity Index is the ratio of IC₅₀ for cytotoxicity versus antiplasmodial activity (L6/P.f.). ^bThe IC₅₀ values are the means of two independent assays; the individual values vary by less than a factor of 2.

Based on the above results, we have further studied the influence of substituent modification around the terminal nitrogen atom in compounds **8** on antimalarial activity. In the previous paper, we demonstrated that the addition of a rigid ureido functionality at the terminus of the 3-aminopropylamino-substituent at

C11 of the neocryptolepine core improved both the antimalarial activity and selectivity index.¹⁷ The ureido derivative of **8c** showed an IC_{50} of 2.2 nM and a SI of 1400, which are 5.3 and 61 times higher than those of **8c**, respectively. Accordingly, a series of ureido and thioureido derivatives **9**, **10** were prepared in high yields by modification of free terminal amines of **8** with either phenylisocyanate or isothiocyanate in dry CH_2Cl_2 at room temperature, as shown below.

Table 2. The antiplasmodial activity against *P. falciparum* (CQS:NF54) and cytotoxicity towards mammalian L6 cells of the neocryptolepine derivatives **9** and **10**.



Compound	R ¹	R ²	Yield %	L6 cells IC_{50} nM ^b	NF 54 IC_{50} nM ^b	SI ^a L6/NF54	β -Heamatin inhibition IC_{50} μ M ^b
9a	H	Me	91	5647.1	68.7	82.2	26.34
9b	Cl	Me	84	1179.0	19.1	61.7	10.07
10a	H	Me	90	7249.3	57.3	126.5	19.97
10b	Cl	Me	79	3266.5	19.9	164.1	34.11

^aSelectivity Index is the ratio of IC_{50} for cytotoxicity versus antiplasmodial activity (L6/P.f.). ^bThe IC_{50} values are the means of two independent assays; the individual values vary by less than a factor of 2.

The antiplasmodial activities of compounds **9** and **10** were measured against *P. falciparum* (CQS: NF54 strain). All compounds within this series showed antimalarial activity with high selectivity indices and revealed promising drug discovery leads (Table 2). More importantly, ureido and thioureido derivatives **9b** and **10b** with branched three carbon spacers in combination with chlorine atom at C2 of the neocryptolepine core were the most active in this series (IC_{50} of 19.1 nM and 19.9 nM, respectively). It should be noted that compounds with a thioureido functionality are more potent than the corresponding

ureido analogues. Comparing **9b** with **10b**, the antiplasmodial activities were similar, but **10b** bearing a thioureido group showed a three times higher SI.

Some studies revealed that the effectiveness of CQ as an antimalarial drug may be ascribed to its capability of docking with the fastest growing face of the haemozoin crystal. The quinoline ring of CQ interacts with ferriprotoporphyrin IX (Fe(III)PPIX) by π - π stacking, and in addition the 4-amino group of CQ interacts with haematin by a weak hydrogen bonding interaction. The resulting haematin-CQ complex directly exerts a toxic effect on the parasite.²⁶ We tested the β -haematin inhibition of the 11-(ω -aminoalkylamino)indolo[2,3-*b*]quinolones and their ureido and thioureido derivatives. Compounds **8b**, **8d**, **8f** and **8g** with a branched ω -aminoalkylamino substituent showed weak β -haematin inhibition. The compound **8e** with a hydroxylated pendant showed slightly increased β -haematin inhibition, which may be attributed to the improved hydrophilicity of the polar hydroxy group. Compounds **9** and **10** with ureido and thioureido functionalities showed greater β -haematin inhibition. In particular **9b** showed the strongest β -haematin inhibition with IC₅₀ value of 10.07 μ M. The reason for the improved inhibition may be due to the increased π - π stacking ability of the derivatives containing ureido and thioureido groups with haem, resulting from the delocalized electrons in the planar urea/thiourea-phenyl systems.

In conclusion, we have prepared a novel series of neocryptolepine derivatives by systematically varying the structure and length of the linker between the two nitrogen atoms on the neocryptolepine core. All the synthesized compounds showed more potent antiplasmodial activities against CQS parasites (NF54 strain) *in vitro* when compared with neocryptolepine. A comparative study showed that compounds containing linear-side chains with three carbon atoms spacers between the two distal nitrogen generally present better antiplasmodial activities than those with branched carbon atoms spacers. Further variations in substituents and substitution patterns may be necessary to obtain nontoxic compounds showing better activity and selectivity.

EXPERIMENTAL

The ¹H NMR, ¹³C NMR spectra were measured on the Varian INOVA-600 or Varian INOVA-400 spectrometer, using CDCl₃ or DMSO-*d*₆ as solvent and tetramethylsilane (TMS) as the internal standard.

General procedure for the synthesis of 11-aminoneocryptolpines 8a–8g: 11-Chloroindoloquinolines **7** (0.3 mmol) and an excess of the appropriate aminoalkylamine (3.0 mmol) were heated together at 120 °C for 4 h. TLC monitoring was used to ensure the completion of reaction. The resulting brown crude oil was purified by flash chromatography using AcOEt-2N ammonia in MeOH (9:1v/v) as an eluent to yield pure yellowish solids product.

***N*-(3-Amino-2,2-dimethylpropyl)-5-methyl-5*H*-indolo[2,3-*b*]quinolin-11-amine (8b):** Yield 280 mg (84%), yellow solids; mp 112–114 °C; ¹H NMR (300MHz, CDCl₃) δ 8.39 (br s, 1H), 8.11 (d, *J* = 8.3 Hz,

1H), 7.99 (d, $J = 7.8$ Hz, 1H), 7.76 (d, $J = 8.0$ Hz, 1H), 7.61 (dt, $J = 17.0, 8.5$ Hz, 2H), 7.39–7.33 (m, 1H), 7.29–7.24 (m, 1H), 7.19–7.16 (m, 1H), 4.20 (s, 3H), 3.83 (s, 2H), 2.83 (s, 2H), 0.86 (s, 6H); ^{13}C NMR (151MHz, CDCl_3) δ 157.56, 152.53, 149.42, 138.20, 130.25 (d), 125.02, 124.20, 123.58, 122.22, 120.55, 118.59, 117.32, 116.20, 114.73, 104.53, 61.79, 53.35, 36.03, 32.95 (d), 23.92 (d) (2C). HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{24}\text{N}_4$ [M-H] $^-$. Exact mass: 332.4421, found 331.4462.

***N*-(3-Amino-2,2-dimethylpropyl)-2-chloro-5-methyl-5*H*-indolo[2,3-*b*]quinolin-11-amine (8d):** Yield 248 mg (95%), yellow solids; mp 177–179 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.07 (d, $J = 1.9$ Hz, 1H), 7.97 (d, $J = 8$ Hz, 1H), 7.76 (d, $J = 7.9$ Hz, 1H), 7.54 (dd, $J = 5.0, 4.1$ Hz, 1H), 7.49 (t, $J = 7.4$ Hz, 1H), 7.41 (t, $J = 7.6$ Hz, 1H), 7.18 (t, $J = 7.5$ Hz, 1H), 4.18 (s, 3H), 3.78 (s, 2H), 2.84 (s, 2H), 0.86 (s, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 148.44, 136.82, 130.40 (2C), 126.31, 125.70 (2C), 124.69, 124.02 (2C), 122.47 (2C), 119.21, 117.54, 116.36, 62.08, 53.49, 36.01, 33.41, 24.09 (2C). HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{23}\text{ClN}_4$ [M-H] $^-$. Exact mass: 366.1611, found 365.1624.

1-Amino-3-(2-chloro-5-methyl-5*H*-indolo[2,3-*b*]quinolin-11-ylamino)propan-2-ol (8e): Yield 290 mg (82%), yellow solids; mp 150–152 °C; ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 8.56 (d, $J = 2.1$ Hz, 1H), 7.95 (d, $J = 7.8$ Hz, 1H), 7.85 (d, $J = 9.2$ Hz, 1H), 7.78 (dd, $J = 9.1, 2.1$ Hz, 1H), 7.50 (d, $J = 7.8$ Hz, 1H), 7.28 (t, $J = 7.5$ Hz, 1H), 7.07 (d, $J = 14.2$ Hz, 1H), 4.13 (s, 3H), 3.91–3.87 (m, 1H), 3.79 (dd, $J = 12.8, 6.5$ Hz, 2H), 3.69–3.66 (m, 2H); ^{13}C NMR (101MHz, $\text{DMSO-}d_6$) δ 156.17, 152.45, 147.55, 136.10, 130.17, 124.92 (2C), 123.91, 123.40, 122.21, 118.19, 117.01, 116.77, 116.67, 105.46, 70.97, 52.32, 45.41, 32.34. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{19}\text{ClN}_4\text{O}$ [M-H] $^-$. Exact mass: 354.1247, found 353.1275.

***N*-(2-Aminopropyl)-2-chloro-5-methyl-5*H*-indolo[2,3-*b*]quinolin-11-amine (8f):** Yield 297 mg (87%), yellow solids; mp 95–79 °C; ^1H NMR (600 MHz, CDCl_3) δ 8.10 (d, $J = 5.7$ Hz, 2H), 7.76 (d, $J = 7.9$ Hz, 1H), 7.61–7.59 (m, 1H), 7.54 (d, $J = 9.1$ Hz, 1H), 7.44 (t, $J = 7.6$ Hz, 1H), 7.22 (t, $J = 7.5$ Hz, 1H), 6.48 (br, 1H), 4.24–4.18 (m, 3H), 3.79 (d, $J = 11.8$ Hz, 1H), 3.40 (t, $J = 6.0$ Hz, 1H), 3.12 (dd, $J = 4.4, 1.7$ Hz, 1H), 1.10 (d, $J = 6.3$ Hz, 6H); ^{13}C NMR (151MHz, CDCl_3) δ 156.16, 152.66, 147.82 (d), 136.95 (d), 130.52, 130.41 (d), 127.01, 126.22 (d), 124.45, 121.75 (d), 119.41 (d), 117.57, 116.40 (d), 107.63, 55.20 (d), 47.90 (d), 33.17 (d), 22.95 (d). HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{19}\text{ClN}_4$ [M-H] $^-$. Exact mass: 338.1298, found 337.1232.

***N*-(2-Amino-2-methylpropyl)-2-chloro-5-methyl-5*H*-indolo[2,3-*b*]quinolin-11-amine (8g):** Yield 320 mg (90%), yellow solids; mp 108–110 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.15 (dd, $J = 12.5, 4.9$ Hz, 2H), 7.76 (d, $J = 8.0$ Hz, 1H), 7.62 (dt, $J = 19.8, 5.3$ Hz, 2H), 7.44 (t, $J = 7.6$ Hz, 1H), 7.21 (t, $J = 7.5$ Hz, 1H), 6.73 (br, 1H), 4.22 (d, $J = 0.4$ Hz, 3H), 3.58 (d, $J = 4.5$ Hz, 2H), 1.11 (s, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 156.47, 152.91, 148.22, 137.17, 130.43 (d), 126.12 (2C), 124.58 (2C), 121.64 (2C) 119.40 (d), 117.67, 116.83 (d), 107.63, 59.14, 51.50, 33.16, 29.50 (2C). HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{21}\text{ClN}_4$ [M-H] $^-$. Exact mass: 352.1455, found 351.1422.

General procedure for the synthesis of compounds 9a–9f: 2-Substituted 5-methyl-5*H*-indolo[2,3-*b*]quinolin-11-amine (**8a–g**, 50 mg) was completely dissolved in dry CH₂Cl₂ (1 mL), and then a solution of phenylisocyanate or phenylisothiocyanate (1.1 equiv) and dry CH₂Cl₂ (1 mL) were added drop by drop under stirring at room temperature for 2–4 h. Tlc monitoring was used to ensure the completion of reaction. The reaction mixture was evaporated to dryness under reduced pressure. The crude product was purified by flash chromatography using AcOEt-2*N* ammonia in MeOH (9:1 v/v) as an eluent to yield pure products as yellowish solids.

1-(2,2-Dimethyl-3-(5-methyl-5*H*-indolo[2,3-*b*]quinolin-11-ylamino)propyl)-3-phenylurea (9a): Yield 412 mg (91%), yellow solids; mp 154–156 °C; ¹H NMR (600 MHz, CDCl₃) δ 9.25 (s, 1H), 8.42 (d, *J* = 5.7 Hz, 1H), 7.74–7.70 (m, 2H), 7.64 (d, *J* = 5.6 Hz, 1H), 7.47 (s, 2H), 7.40–7.35 (m, 2H), 7.24–7.22 (m, 2H), 7.14 (d, *J* = 2.8 Hz, 1H), 6.97 (d, *J* = 2.9 Hz, 2H), 6.77 (s, 1H), 6.64 (s, 1H), 4.03 (d, *J* = 2.8 Hz, 3H), 3.60 (s, 2H), 3.25 (s, 2H), 2.29 (br, 1H), 0.63 (d, *J* = 2.2 Hz, 6H); ¹³C NMR (151 MHz, CDCl₃) δ 158.01, 157.18, 151.56, 149.62, 140.05, 137.95, 130.96, 129.53 (2C), 126.04, 124.40, 124.25, 123.19, 122.67, 121.99, 120.00 (2C), 119.73, 116.93, 116.59, 115.04, 106.85, 55.71, 48.02, 38.61, 33.30, 24.07 (2C). HRMS (ESI) calcd for C₂₈H₂₉N₅O [M-H]⁺. Exact mass: 451.2372, found 450.2364.

1-(3-(2-Chloro-5-methyl-5*H*-indolo[2,3-*b*]quinolin-11-ylamino)-2,2-dimethylpropyl)-3-phenylurea (9b): Yield 410 mg (84%), yellow solids; mp 232–234 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.37 (s, 1H), 8.13 (br, 1H), 7.73–7.70 (m, 2H), 7.60–7.57 (m, 1H), 7.45 (dd, *J* = 8.0, 4.7 Hz, 3H), 7.39 (t, *J* = 7.4 Hz, 1H), 7.14–7.06 (m, 2H), 7.31 (t, *J* = 7.2 Hz, 2H), 6.53 (br, 1H), 5.91 (br, 1H), 4.12 (d, *J* = 5.5 Hz, 3H), 3.57 (d, *J* = 6.2 Hz, 2H), 3.31 (d, *J* = 6.0 Hz, 2H), 0.73 (s, 2H), 0.73 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 157.75, 156.80, 148.24, 139.72, 136.45, 130.92, 129.70 (2C), 127.36, 126.62, 124.04 (2C), 123.94, 123.75, 122.68, 120.69 (2C), 120.01, 117.92, 116.98, 116.46, 106.85, 55.97, 48.31, 38.44, 33.49, 24.18 (2C). HRMS (ESI) calcd for C₂₈H₂₈ClN₅O [M-H]⁺. Exact mass: 485.1982, found 484.1918.

1-(2,2-Dimethyl-3-(5-methyl-5*H*-indolo[2,3-*b*]quinolin-11-ylamino)propyl)-3-phenylthiourea (10a): Yield 42 mg (90%), yellow solids; mp 172–174 °C; ¹H NMR (600 MHz, CDCl₃) δ 8.54 (d, *J* = 7.7 Hz, 1H), 7.86 (d, *J* = 7.0 Hz, 1H), 7.76 (dd, *J* = 15.1, 7.2 Hz, 2H), 7.66 (d, *J* = 8.1 Hz, 1H), 7.46 (t, *J* = 6.7 Hz, 1H), 7.39 (dd, *J* = 17.1, 8.2 Hz, 3H), 7.33 (d, *J* = 6.4 Hz, 2H), 7.24 (dd, *J* = 18.7, 11.6 Hz, 1H), 6.89 (s, 1H), 4.24 (s, 3H), 3.79 (d, *J* = 4.2 Hz, 2H), 3.73 (d, *J* = 4.2 Hz, 2H), 1.96 (br, 1H), 0.72 (s, 6H); ¹³C NMR (151 MHz, CDCl₃) δ 182.53, 153.42, 151.07, 145.53, 138.59, 137.49, 132.00, 129.50 (2C), 126.44, 126.24, 125.25 (2C), 125.01, 123.39, 123.16, 122.73, 121.14, 117.18, 115.42, 115.19, 103.55, 54.75, 51.84, 39.27 (d), 34.68, 24.30 (d) (2C). HRMS (ESI) calcd for C₂₈H₂₉N₅S [M-H]⁺. Exact mass: 467.2144, found 466.2170.

1-(3-(2-Chloro-5-methyl-5*H*-indolo[2,3-*b*]quinolin-11-ylamino)-2,2-dimethylpropyl)-3-phenylthiourea (10b): Yield 401 mg (79%), yellow solids; mp 155–157 °C; ¹H NMR (600 MHz, CDCl₃) δ 8.56 (br, 1H), 8.50 (d, *J* = 3.8 Hz, 1H), 7.87–7.85 (m, 1H), 7.73–7.71 (m, 1H), 7.60 (dd, *J* = 8.7, 6.3 Hz, 1H), 7.51 (dd,

$J = 9.0, 6.2$ Hz, 1H), 7.42–7.37 (m, 3H), 7.31 (ddd, $J = 10.8, 9.8, 4.6$ Hz, 3H), 7.19 (dd, $J = 13.6, 6.8$ Hz, 1H), 6.61 (br, 1H), 4.15 (d, $J = 6.2$ Hz, 3H), 3.76 (d, $J = 5.9$ Hz, 2H), 3.65 (t, $J = 5.8$ Hz, 2H), 1.99 (br, 1H), 0.66 (d, $J = 6.0$ Hz, 6H); ^{13}C NMR (151MHz, CDCl_3) δ 182.15, 157.42, 152.91, 147.77, 136.64, 136.55, 130.86, 130.67 (2C), 128.15, 127.22, 126.51, 126.00 (2C), 124.11 (2C), 122.96, 119.60, 117.89, 117.53, 116.46, 108.04, 54.79, 52.92, 39.13, 33.42, 24.15 (2C). HRMS (ESI) calcd for $\text{C}_{28}\text{H}_{28}\text{ClN}_5\text{S}$ [M-H] $^-$. Exact mass: 501.1754, found 500.1777.

ACKNOWLEDGEMENTS

We are grateful to Okayama University for its support by Promotion of Graduate Course Students for E.S. and to the Advanced Science Research Center for the NMR experiments and EA by Ms. M. Kosaka and Mr. M. Kobayashi. This study was partially supported by the Adaptable and Seamless Technology Transfer Program of JST. TJE acknowledges the National Research Foundation and Medical Research Council of South Africa and University of Cape Town for the financial support.

REFERENCES

1. A. Martinelli, R. Moreira, and P. V. L. Cravo, *Mini-Rev. Med. Chem.*, 2008, **8**, 201.
2. D. A. Fidock, R. T. Eastman, S. A. Ward, and S. R. Meshnick, *Trends Parasitol.* 2008, **24**, 537.
3. R. G. Ridley, *Nature*, 2002, **415**, 686.
4. K. Kaur, M. Jain, T. Kaur, and R. Jain, *Bioorg. Med. Chem.*, 2009, **17**, 3229.
5. V. Kumar, A. Mahajan, and K. Chibale, *Bioorg. Med. Chem.*, 2009, **17**, 2236.
6. A. U. Krettli, J. O. Adebayo, and L. G. Krettli, *Curr. Drug Targets*, 2009, **10**, 261.
7. M. A. van Agtmael, T. A. Eggelte, and C. J. van Boxtel, *Trends Pharmacol. Sci.*, 1999, **20**, 199.
8. P. G. Bray, S. A. Ward, and P. M. O'Neill, *Drugs Dis. Post-Genom. Biol.*, 2005, **295**, 3.
9. Y. J. Xu and L. Pieters, *Mini-Rev. Med. Chem.*, 2013, **13**, 1056.
10. K. Cimanga, T. D. Bruyne, L. Pieters, M. Claeys, and A. Vlietinck, *Tetrahedron Lett.*, 1996, **37**, 1703.
11. E. Kumar, J. R. Etukala, and S. Y. Ablordeppey, *Mini Rev. Med. Chem.*, 2008, **8**, 538.
12. I. El Sayed, P. V. Veken, L. Dhooche, S. Hostyn, G. Van Baelen, G. Lemièrè, B. U. W. Maes, P. Cos, L. Maes, J. Joossens, A. Haemers, L. Pieters, and K. Augustyns, *J. Med. Chem.*, 2009, **52**, 2979.
13. T. H. M. Jonckers, S. Van Miert, C. Kanyanga, C. Bailly, P. Colson, M. C. De Pauw-Gillet, H. van Den Heuvel, M. Claeys, F. Lemièrè, E. L. Esmans, J. Rozenski, L. Quirijnen, L. Maes, R. Dommissè, G. L. F. Lemièrè, A. Vlietinck, and L. Pieters, *J. Med. Chem.*, 2002, **45**, 3497.
14. J. Lavrado, R. Moreira, and A. Paulo, *Curr. Med. Chem.*, 2010, **17**, 2348.
15. W. J. Lu, M. Świtalska, L. Wang, M. Yonezawa, I. E. El Sayed, J. Wietrzyk, and T. Inokuchi, *Med. Chem. Res.*, 2013, **22**, 4492.

16. T. P. Prakash, S. P. Perunninakulath, and G. T. Santosh, [*Curr. Org. Chem.*, 2011, **15**, 1036.](#)
17. Z. W. Mei, L. Wang, W. J. Lu, C. Q. Pang, T. Maeda, W. Peng, M. Kaiser, I. E. El Sayed, and T. Inokuchi, [*J. Med. Chem.*, 2013, **56**, 1431.](#)
18. W. J. Lu, K. J. Wicht, L. Wang, K. Imai, Z. W. Mei, M. Kaiser, I. E. El Sayed, T. J. Egan, and T. Inokuchi, [*J. Med. Chem.*, 2013, **64**, 498.](#)
19. I. El Sayed, F. Ramzy, S. William, M. El Bahanasawy, and M. M. Abdel-Staar, [*Med. Chem. Res.*, 2012, **21**, 4219.](#)
20. S. El Bardicy, I. El-Sayed, F. Yousif, M. El Bahansawye, P. Van der Veken, A Haemers, K. Augustyns, and L. Pieters, [*Pharm. Biol.*, 2012, **50**, 134.](#)
21. L. Wang, M. Świtalska, Z. W. Mei, W. J. Lu, Y. Takahara, X. W. Feng, I. E. Sayed, J. Wietrzyk, and T. Inokuchi, [*Bioorg. Med. Chem.*, 2012, **20**, 4820.](#)
22. C. Bailly, W. Laine, B. Baldeyrou, M. C. De Pauw-Gillet, P. Colson, C. Houssier, K. Cimanga, S. Van Miert, A. J. Vlietinck, and L. Pieters, *Anti-Cancer Drug Des.*, 2000, **15**, 191.
23. L. Dassonneville, A. Lansiaux, A. Wattelet, N. Wattez, C. Mahieu, S. Van Miert, L. Pieters, and C. Bailly, [*Eur. J. Pharmacol.*, 2000, **409**, 9.](#)
24. P. A. Stocks, K. J. Raynes, P. G. Bray, B. K. Park, P. M. O'Neill, and S. A. Ward, [*J. Med. Chem.*, 2002, **45**, 4975.](#)
25. D. Y. De, F. M. Krogstad, F. B. Cogswell, and D. J. Krogstad, *Am. J. Trop. Med. Hygien.*, 1996, **55**, 579.
26. P. M. O'Neill, P. G. Bray, S. R. Hawley, S. A. Ward, B. K. Park, [*Pharmacol. Therapeut.*, 1998, **77**, 29.](#)